Optune Therapy Clinical Trials

Tumor

TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma

CONTACT:
Sonisha A. Warren, PhD
Phone:352.294.8737
Email: sonisha.warren@neurosurgery.ufl.edu

2-THE-TOP: Phase 2, Single Arm, Historically Controlled Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients with Newly Diagnosed Glioblastoma

CONTACT:
Sonisha A. Warren, PhD
Phone:352.294.8737
Email: sonisha.warren@neurosurgery.ufl.edu

PRECISION: A Phase II Study of the Optune System, Enhanced by Genomic Analysis to Identify the Genetic Signature of Response in the Treatment of Recurrent Glioblastoma Multiforme

CONTACT:
Sonisha A. Warren, PhD
Phone:352.294.8737
Email: sonisha.warren@neurosurgery.ufl.edu

FORWARD: A Phase 2, Historically Controlled Study Testing the Efficacy of TTFields (Optune®) With Adjuvant Temozolomide in High Risk WHO Grade II and III Astrocytomas (FORWARD)

CONTACT:
Annie Allen, MBA
Phone:352.294.8836
Email: Forward-Study@ufl.edu